In addition to the question of how to classify the latest test results on benzoyl peroxide (BPO) preparations used in acne treatment, the results of clinical studies on bimekizumab and new drug candidates such as vilobelimab and LAD191 in hidradenitis suppurativa (HS) were presented.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- AAD Annual Meeting: Review
HS and acne – what’s new?
- New perspectives for the optimization of cancer immunotherapy
Nanoparticle-mediated intratumoral gene editing of PD-L1 and galectin-9
- Past, present and future
Biomarkers in schizophrenia
- From genome profiles to targeted therapies
Advances in breast cancer therapy in the age of molecular diagnostics
- Current overview of evidence, mechanisms and clinical implications
Apolipoprotein E and neuropsychiatric symptoms in neurocognitive disorders
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Parkinson's disease
Individual therapy management for an optimized outcome – an update
- Latent autoimmune diabetes in adults (LADA)